In a major medical breakthrough, a revolutionary solution for Crohn’s disease and colitis has been discovered, bringing hope and relief to millions of patients worldwide. Brought to you by IGC, located in Tel Aviv, this innovative solution, PH Gastrilex, is set to transform the way we manage chronic inflammatory diseases.

Discovery of the Mechanism

The breakthrough behind PH Gastrilex was discovered by the scientists at Ben Gurion University and is rooted in the fascinating biology of the Australian blue crayfish, which has the unique ability to convert minerals into their amorphous form. These amorphous particles are a million times smaller in volume, allowing them to travel freely in the bloodstream and reach inflamed areas efficiently. This choice was inspired by the blue crayfish’s status as the fastest regenerating animal on the planet, capable of regenerating its entire body, armor, muscles, and other parts at an incredible speed, even in a mineral-deficient freshwater environment. This is unlike other crabs that live in mineral-rich saltwater. It’s important to note that PH Gastrilex mimics the crayfish’s ability to transform minerals into their amorphous form without harming the animals. Once these particles arrive at the site of inflammation, they perform a hybrid action: balancing the pH levels, which are typically unbalanced in inflamed areas, and boosting the growth of the patient’s own stem cells. These stem cells then work to repair the damaged tissue.

NASA Collaboration

Groundbreaking work on PH Gastrilex has caught the attention of NASA. Recent experiments conducted on the International Space Station (ISS) have demonstrated the efficacy of Amorphous Calcium Carbonate (ACC) in extreme environments. These experiments showed that ACC not only enhances cell growth and differentiation but also significantly reduces inflammation, even in the challenging conditions of space. This discovery is particularly exciting for Crohn’s and colitis patients, as it underscores the robustness and potential of PH Gastrilex.

״This technology is definitely the new blue ocean in the category of fighting chronic inflammation״ – Ram Shechter

 

How PH Gastrilex Works

PH Gastrilex utilizes the unique properties of ACC to balance pH levels at inflammation sites in the body. This is a completely new approach to combating chronic inflammation, providing a “blue ocean” strategy for long-term relief. Unlike traditional anti-inflammatory treatments, which often have adverse side effects and are not recommended for long-term use, PH Gastrilex is safe for extended periods, even decades. It’s so safe for long term use that it has been approved as a supplement by the (MOH). Moreover, PH Gastrilex offers a remarkable benefit by boosting the body’s own stem cells. Stem cell treatments are typically expensive and inaccessible for many patients. However, PH Gastrilex promotes the renewal of the body’s stem cells, helping to repair damaged areas naturally and effectively. This not only accelerates healing but also rejuvenates the body without any collateral damage.

Impressive Patient Outcomes

The success of PH Gastrilex is backed by compelling patient testimonials and outcomes. According to data from IGC users, 80% of Crohn’s disease patients who started taking PH Gastrilex achieved full symptom control within six weeks, sometimes even less. These patients reported significant  improvements in their quality of life, experiencing fewer symptoms and a greater ability to maintain normal daily activities.

Medical Journal Coverage

The innovative capabilities of ACC have garnered extensive coverage in global medical journals, showcasing its potential in battling all kinds of inflammation diseases. Notable publications include:

● Life Sciences in Space Research: Published findings on the success of ACC in promoting stem cell growth and differentiation in the extreme conditions of space, indicating even greater potential for managing inflammation and boosting stem cell growth on Earth.

● ClinicalTrial: Documented remarkable outcomes in COVID-19 treatment, with patients experiencing swift recovery and reduced necessity for intensive care.

● JARG: Published significant advancements in embryo development through the use of ACC, highlighting its potential to increase IVF success rates.

● Cancers (MDPI): Featured promising research on ACC’s efficacy in treating lung cancer, based on pre-clinical and in vitro studies.

● Nanotech Now and Science Daily: Discussed ACC’s superior absorption and bioavailability  compared to other calcium supplements.

● MDPI: Highlighted a study demonstrating performance enhancements in female athletes using ACC-based supplements.

A New Era for Inflammatory Disease Management

A New Era for Inflammatory Disease Management IGC, with offices in Tel Aviv, has taken upon themselves to lead the management of chronic inflammation with solutions from the newest technologies available. This breakthrough is not just a step forward for the company, but a giant leap for patients battling Crohn’s disease, colitis, and other chronic inflammatory diseases. With PH Gastrilex now available exclusively through IGC, patients worldwide have a new, effective, and safe option for managing their conditions. This revolutionary solution is set to change the landscape of inflammatory disease management, offering hope and relief to millions around the world.

IGC is expanding beyond the boundaries of Tel Aviv and enabling people around the world to access this solution. Therefore, IGC is looking for the first 100 people who can provide testimonials on the improvement of their condition after trying the product.

For more information click here